Michelis Regina, Sela Shifra, Ben-Zvi Ilan, Nagler Rafael M
Eliachar Research Laboratory, Western Galilee Hospital, Nahariya, Israel.
Blood Purif. 2007;25(5-6):505-9. doi: 10.1159/000113010. Epub 2008 Jan 11.
Beta2-microglobulin (beta2m) is a major component in dialysis-related amyloidosis, a disabling disease affecting long-term dialysis patients.
Beta2m and other components were analyzed in saliva and serum from 53 individuals in 4 subgroups: healthy normal controls, diabetes mellitus (DM), chronic kidney disease (CKD) and hemodialysis (HD) patients.
Median salivary and mean serum beta2m concentrations were 78% higher in both saliva (p = 0.048) and serum (p = 0.047) in DM patients; 118% (p = 0.016) and 907% (p = 0.007) higher, respectively, in CKD patients, and 328% (p = 0.0001) and 2,710% (p = 0.001) higher, respectively, in HD patients, compared with healthy controls. The correlation analysis between salivary and serum beta2m concentrations showed a low correlation rate in HD patients (r = -0.18), but was rather high in CKD patients (r = 0.50).
Salivary analysis of beta2m is a reliable method for evaluating serum beta2m levels in CKD patients, and may help predict the potential for development of CKD-induced amyloidosis.
β2-微球蛋白（β2m）是透析相关淀粉样变性的主要成分，这是一种影响长期透析患者的致残性疾病。
对4个亚组的53名个体的唾液和血清中的β2m及其他成分进行分析，这4个亚组分别为：健康正常对照组、糖尿病（DM）患者、慢性肾脏病（CKD）患者和血液透析（HD）患者。
与健康对照组相比，DM患者唾液中β2m浓度中位数和血清中β2m平均浓度分别高出78%（唾液中p = 0.048，血清中p = 0.047）；CKD患者分别高出118%（p = 0.016）和907%（p = 0.00）；HD患者分别高出328%（p = 0.0001）和2710%（p = 0.001）。唾液和血清β2m浓度之间的相关性分析显示，HD患者的相关性较低（r = -0.18），而CKD患者的相关性较高（r = 0.50）。
对β2m进行唾液分析是评估CKD患者血清β2m水平的可靠方法，可能有助于预测CKD诱导的淀粉样变性的发生可能性。
